|
1.
|
|
36 p, 4.7 MB |
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
/
García-Vílchez, Raquel (Instituto de Investigación Biomédica de Salamanca) ;
Añazco-Guenkova, Ana M. (Instituto de Investigación Biomédica de Salamanca) ;
Dietmann, Sabine (Washington University School of Medicine in St. Lou) ;
López, Judith (Instituto de Investigación Biomédica de Salamanca) ;
Morón-Calvente, Virginia (Instituto de Investigación Biomédica de Salamanca) ;
D'Ambrosi, Silvia (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Nombela, Paz (Instituto de Investigación Biomédica de Salamanca) ;
Zamacola, Kepa (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Mendizabal, Isabel (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
García-Longarte, Saioa (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Zabala-Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ;
Astobiza, Ianire (Centro de Investigación Biomédica en Red de Cáncer) ;
Fernández, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ;
Paniagua, Alejandro (Universidad de Salamanca) ;
Miguel-López, Borja (Instituto de Investigación Biomédica de Salamanca) ;
Marchand, Virginie (Université de Lorraine, France) ;
Alonso-López, Diego (Universidad de Salamanca) ;
Merkel, Angelika (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Tuñón, Ignacio (Universidad de Salamanca) ;
Ugalde-Olano, Aitziber (Hospital de Basurto (Bilbao, Biscaia)) ;
Loizaga-Iriarte, Ana (Hospital de Basurto (Bilbao, Biscaia)) ;
Lacasa-Viscasillas, Isabel (Hospital de Basurto (Bilbao, Biscaia)) ;
Unda, Miguel (Hospital de Basurto (Bilbao, Biscaia)) ;
Azkargorta, Mikel (Carlos III Networked Proteomics Platform (ProteoRed-ISCIII), Madrid) ;
Elortza, Félix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Bárcena, Laura (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Gonzalez-Lopez, Monika (CIC bioGUNE, Basque Research and Technology Alliance (BRTA)) ;
Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Di Domenico, Tomás (Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO)) ;
Sánchez-Martín, Manuel A. (Universidad de Salamanca) ;
De Las Rivas, Javier (Universidad de Salamanca) ;
Guil, S. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Motorin, Yuri (Université de Lorrain) ;
Helm, Mark (Johannes Gutenberg-University Mainz, Germany) ;
Pandolfi, Pier Paolo (University of Turin, Italy) ;
Carracedo, Arkaitz (Centro de Investigación Biomédica en Red de Cáncer) ;
Blanco, Sandra (Universidad de Salamanca)
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. [...]
2023 -  10.1186/s12943-023-01809-8
Molecular cancer, Vol. 22 Núm. 1 (july 2023)
|
|
|
2.
|
|
9 p, 1.2 MB |
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
/
Gonzalez-Montes, Yolanda (Universitat de Girona) ;
Rodriguez-Romanos, Rocío (Universitat de Girona) ;
Villavicencio, Alicia (Universitat de Girona) ;
Osca-Gelis, Gemma (Universitat de Girona) ;
González-Bártulos, Marta (Universitat de Girona) ;
Llopis, Francesca (Universitat de Girona) ;
Clapes, Victòria (Hospital Universitari de Bellvitge) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Escoda, Lourdes (Universitat Rovira i Virgili) ;
Sarrà, Josep (Universitat Rovira i Virgili) ;
Garzó, Ana (Universitat de Girona) ;
Lloveras, Natàlia (Universitat de Girona) ;
Díez, Isabel (Universitat de Girona) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gallardo, David (Universitat de Girona)
Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. [...]
2023 - 10.3389/fimmu.2023.1158105
Frontiers in immunology, Vol. 14 (april 2023)
|
|
|
3.
|
|
16 p, 2.1 MB |
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies : a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
/
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Sanmartín, O. (Fundació Institut Valencià d'Oncologia) ;
Gúrpide, A. (Clínica Universidad de Navarra) ;
España, A. (Clínica Universidad de Navarra) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Suh Oh, H.J. (Complejo Hospitalario Universitario de Pontevedra) ;
Aragón, I. (Complejo Hospitalario Universitario de Huelva) ;
Segura, S. (Hospital del Mar (Barcelona, Catalunya)) ;
Beato, C. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Botella, R. (Instituto de Investigación Sanitaria La Fe) ;
Universitat Autònoma de Barcelona
Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). [...]
2019 - 10.1007/s12094-018-1953-x
Clinical & Translational Oncology, Vol. 21 Núm. 5 (january 2019) , p. 556-571
|
|
|
4.
|
|
11 p, 822.0 KB |
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
/
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
De Velasco, G. (Hospital 12 de Octubre (Madrid)) ;
Lainez, N. (Complejo Hospitalario de Navarra) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Muñoz-Langa, J. (Hospital Universitari i Politècnic La Fe (València)) ;
Pérez-Valderrama, B. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Basterretxea, Laura (Hospital Donostia-Donostia Ospitalea) ;
Caballero, C. (Hospital General Universitario de Valencia) ;
Vazquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. [...]
2019 - 10.1007/s12094-018-02001-x
Clinical & Translational Oncology, Vol. 21 Núm. 1 (25 2019) , p. 64-74
|
|
|
5.
|
|
11 p, 918.0 KB |
Brief Research Report : Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
/
Sisteré-Oró, Marta (Universitat Pompeu Fabra) ;
Wortmann, Diana D. J. (Universitat Pompeu Fabra) ;
Andrade, Naína (Universitat Pompeu Fabra) ;
Aguilar-Hernández, Andrés (Hospital Quiron-Dexeus Barcelona) ;
Mayo de las Casas, Clara (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Casabal, Florencia Garcia (Hospital Quiron-Dexeus Barcelona) ;
Torres, Susana (Hospital Quiron-Dexeus Barcelona) ;
Bona Salinas, Eduardo (Hospital Quiron-Dexeus Barcelona) ;
Raventos Soler, Laura (Hospital Quiron-Dexeus Barcelona) ;
Arcas, Andrea (Hospital Quiron-Dexeus Barcelona) ;
Esparre, Carlos (Hospital Quiron-Dexeus Barcelona) ;
Garcia, Beatriz (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Valarezo, Joselyn (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Güerri-Fernández, Robert (Hospital del Mar (Barcelona, Catalunya)) ;
Gonzalez-Cao, Maria (Hospital Quiron-Dexeus Barcelona) ;
Meyerhans, Andreas (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2 infection, and therefore are a priority group for receiving COVID-19 vaccination. From the patients with advanced solid tumors, about 20% respond very efficiently to immunotherapy with anti-PD1/PD-L1 antibodies and achieve long lasting cancer responses. [...]
2022 - 10.3389/fimmu.2022.908108
Frontiers in immunology, Vol. 13 (july 2022)
|
|
|
6.
|
|
13 p, 368.5 KB |
Dynamic changes in circulating tumor assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in
/
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Valdivia, Augusto (Vall d'Hebron Institut d'Oncologia) ;
Priano, Ilaria (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Lenza, Laura (Vall d'Hebron Institut d'Oncologia) ;
Soleda, Mireia (Vall d'Hebron Institut d'Oncologia) ;
Gonzalo-Ruiz, Javier (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Sansó, Miriam (Institut d'Investigació Sanitària Illes Balears) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. [...]
2023 - 10.1002/1878-0261.13409
Molecular Oncology, Vol. 17 (march 2023) , p. 779-791
|
|
|
7.
|
|
8 p, 696.1 KB |
Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study
/
Gómez-Puerta, José A. (Universitat de Barcelona. Departament de Medicina) ;
Lobo-Prat, David (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Pérez-García, Carolina (Hospital del Mar (Barcelona, Catalunya)) ;
Ponce, Andrés (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Frade-sosa, Beatriz (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Millán Arciniegas, Ana Milena (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Ojeda, Fabiola (Hospital del Mar (Barcelona, Catalunya)) ;
Ruiz-Esquide, Virginia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Corominas, Hèctor (Institut d'Investigació Biomèdica Sant Pau)
Objectives: To describe different clinical patterns of rheumatic immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICI) and their rheumatic and oncologic outcomes. Methods: We classified clinical syndromes according to five different categories: non-inflammatory arthralgias (NIA), rheumatoid arthritis (RA)-like, psoriatic arthritis (PsA)-like, polymyalgia rheumatica (PMR)-like, and a miscellaneous group of patients with other syndromes. [...]
2022 - 10.3389/fmed.2022.888377
Frontiers in Medicine, Vol. 9 (June 2022) , p. 888377
|
|
|
8.
|
|
11 p, 3.4 MB |
PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
/
Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ;
Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ;
Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ;
Boland, Genevieve (Massachusetts General Hospital (Boston)) ;
Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ;
Lewis, Karl D. (University of Colorado Cancer Center) ;
Johnson, Daniel (Ochsner Medical Center) ;
Rivalland, Gareth (University of Auckland & Auckland City Hospital) ;
Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Gogas, Helen (National & Kapodistrian University of Athens) ;
Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ;
Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ;
Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913
|
|
|
9.
|
|
13 p, 2.5 MB |
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
/
Ribeiro, Marcelo Lima (Sao Francisco University Medical School. Laboratory of Immunopharmacology and Molecular Biology) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes Garau, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Miskin, Hari P. (TG Therapeutics (New York)) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Esteller, M. (Institució Catalana de Recerca i Estudis Avançats) ;
Normant, Emmanuel (TG Therapeutics (New York)) ;
Roué, Gaël (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory (R/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody. [...]
2023 - 10.3389/fimmu.2023.1130052
Frontiers in immunology, Vol. 14 (April 2023) , art. 1130052
|
|
|
10.
|
|
9 p, 1.0 MB |
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
/
Cruz, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rodríguez-Romanos, Rocío (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Bartulos, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid)) ;
Heras, Inmaculada (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Buño, Ismael (Hospital General Universitario Gregorio Marañón) ;
Santos, Nazly (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lloveras, Natàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Velarde, Pilar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tuset, Esperanza (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez, Carmen (Hospital Clínic i Provincial de Barcelona) ;
González, Marcos (Hospital Clínico Universitario (Salamanca)) ;
Sanz, Guillermo F. (Hospital Universitari i Politècnic La Fe (València)) ;
Ferrá, Christelle (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Coll, Rosa (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pérez-Simón, Jose A. (Universidad de Sevilla) ;
López-Jiménez, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Jurado, Manuel (Hospital Universitario Virgen de las Nieves (Granada)) ;
Gallardo, David (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule. [...]
2023 - 10.3389/fimmu.2023.1066393
Frontiers in immunology, Vol. 14 (january 2023)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
